title: Regorafenib (Stivarga) and gastrointestinal stromal tumours after treatment failure. Radiological improvement but major adverse effects.
abstract: Regorafenib had no impact on overall survival in a placebo-controlled trial in 199 patients, but adverse effects were frequent and serious. Symptomatic care is a more reasonable choice.
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D010671:Phenylurea Compounds / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib